Serum anti-nucleocapsid antibody correlates of protection from SARS-CoV-2 re-infection regardless of symptoms or immune history.

ABSTRACT:

Background

High spike-based vaccine coverage led to a high seroprevalence of anti-spike (S) antibodies against SARS-CoV-2 in Japanese adults in 2024. Nevertheless, the COVID-19 epidemic continues, and individuals with hybrid immunity are becoming more common in these populations.

Methods

We conducted a prospective cohort study to measure serum anti-SARS-CoV-2 antibody levels in 4496 Japanese adults as part of the national seroepidemiological survey. This study evaluated the correlation between first-visit anti-SARS-CoV-2 antibody levels and their effectiveness in providing protection until the second visit during the Omicron BA.5 epidemic.

Results

Reduced symptomatic infection risk was found to be associated with anti-S antibody, anti-nucleocapsid (N) antibody, and BA

SUBMITTER: Miyamoto S 

PROVIDER: S-EPMC12081900 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature